Home
Scholarly Works
Quantitative risk-benefit analysis of alosetron in...
Conference

Quantitative risk-benefit analysis of alosetron in irritiable bowel syndrome: A patient-level meta-cohort analysis

Authors

Lynd LD; Colley L; Najafzedeh M; Sculpher MJ; Willan AR; Johnson RF; Ozdemir S

Volume

16

Pagination

pp. S183-S183

Publisher

WILEY

Publication Date

August 1, 2007

Conference proceedings

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

ISSN

1053-8569

Contact the Experts team